Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2788882 | 1.00 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1HTTPOLB | |
| SCHEMBL7590836 | 1.00 | KDM4E (0.50) | KDM4ESMN1; SMN2ALDH1A1HTTPOLB | |
| SCHEMBL17865259 | 0.87 | CYP3A4 (0.42) | KDM4ESMN1; SMN2CYP19A1LMNA | |
| SCHEMBL4908140 | 0.85 | CYP3A4 (0.42) | KDM4ESMN1; SMN2ALDH1A1CYP19A1LMNA | |
| SCHEMBL17847834 | 0.85 | CYP17A1 (0.44) | KDM4ESMN1; SMN2ALDH1A1CYP19A1LMNA | |
| SCHEMBL4899497 | 0.84 | HTT (0.45) | SMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL31040269 | 0.84 | SMN1; SMN2 (0.41) | KDM4ESMN1; SMN2ALDH1A1HTTPOLB | |
| SCHEMBL6920072 | 0.84 | MAPK1 (0.45) | KDM4ESMN1; SMN2CYP19A1LMNA | |
| SCHEMBL4910814 | 0.82 | MAPK1 (0.42) | ALDH1A1HTTPOLB | |
| SCHEMBL4910223 | 0.81 | ALDH1A1 (0.50) | ALDH1A1CYP19A1TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1029852-B1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | ESTEVE LABOR DR (ES) | 2002-11-06 | — | — | EP | claimed |
| EP-0808308-B1 | METHOD FOR SEPARATING CARBINOLS | ESTEVE LABOR DR (ES) | 2001-03-07 | — | — | EP | claimed |
| US-6118009-A | Process for obtaining enantiomers of cis-olirtine | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-09-12 | — | — | US | claimed |
| EP-1029852-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-23 | — | — | EP | claimed |
| US-5849931-A | Process for separating carbinols | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 1998-12-15 | — | — | US | claimed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| WO-2016096127-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
| EP-1029852-B1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | ESTEVE LABOR DR (ES) | 2002-11-06 | — | — | EP | disclosed |
| EP-0808308-B1 | METHOD FOR SEPARATING CARBINOLS | ESTEVE LABOR DR (ES) | 2001-03-07 | — | — | EP | disclosed |
| US-6118009-A | Process for obtaining enantiomers of cis-olirtine | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-09-12 | — | — | US | disclosed |
| EP-1029852-A1 | PROCESS FOR OBTAINING ENANTIOMERS OF CIS-OLIRTINE | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-23 | — | — | EP | disclosed |
| US-5849931-A | Process for separating carbinols | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 1998-12-15 | — | — | US | disclosed |
| EP-0808308-A1 | METHOD FOR SEPARATING CARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1997-11-26 | — | — | EP | disclosed |
| WO-1997020817-A1 | METHOD FOR SEPARATING CARBINOLS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | KDM4E 2351/4885SMN1; SMN2 1246/4885ALDH1A1 1431/4885 |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | KDM4E 2431/4885SMN1; SMN2 1262/4885ALDH1A1 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.